Email not displaying correctly? View it in your browser

Call to Action for Latin America
to Boost Innovation and Access
for Neglected Patients in the Region

DNDi’s 4th Partners’ meeting took place this year in Rio de Janeiro, Brazil, on December 2nd. DNDi’s progress in bringing new treatments to neglected patients was reviewed and the main challenges in access to new tools were evaluated, resulting in a Call to Action. More than 260 participants including international health researchers, policy makers, and experts from around the world participated.
Learn more about the meeting
Paediatric Benznidazole Granted Registration in Brazil
Dr Carlos Gadelha, Secretary of Science, Technology and Strategic Products, Brazilian Ministry of Health, announced during DNDi’s 4th Partners’ Meeting that Brazil's National Health Surveillance Agency (ANVISA) granted registration of a new paediatric dosage form of benznidazole, developed through a partnership between DNDi and the State Pharmaceutical Laboratory, LAFEPE.
Read more
Watch the video

Special Clinical Award for Azoles E1224 Project for Chagas Disease 

The project evaluates E1224, a new generation azole compound, as a new tool for the treatment of Chagas disease. DNDi and Eisai Co., Ltd. signed a collaboration and licensing agreement in September 2009. In partnership with Eisai and the Platform of Integral Care for Patients with Chagas Disease - that brings together scientists from CRESIB, Spain, and universities in Bolivia - DNDi launched in 2011 a Phase II study to evaluate safety and efficacy of E1224 in adult patients with chronic indeterminate Chagas infection.
Read more
Watch the video

Registration of ASMQ FDC in India

The Drugs Controller General of India (DCGI) registered the anti-malarial treatment artesunate-mefloquine fixed-dose combination (ASMQ FDC). ASMQ FDC (fixed-dose combination), launched in 2008, was developed in partnership with Farmanguihnos, a Brazilian government-owned pharmaceutical company, and a technology transfer was undertaken for the production of ASMQ FDC by Cipla Ltd., an Indian generic pharmaceutical company. Read more

Publication: Bernard Pécoul quoted in Lancet article on 'The Commission on Macroeconomics and Heatlh: 10 Years On'

Bernard Pécoul emphasized that ‘a new paradigm with opportunities for new pathways for innovation has been formed’ over the past decade but warns that ‘several issues need to be addressed’. Read more
Partnership of the Year Awarded to Chagas Lead Optimization Consortium
In mid-2008, a Lead Optimization Consortium devoted to Chagas disease drug discovery was set up by DNDi. Consortium members are engaged in a complex, iterative process to optimize the efficacy and pharmacological properties of lead compounds while minimizing their toxicity. One of the results of the Consortium is the move of fenarimol series to pre-clinical stage. Partners include: Centre for Drug Candidate Optimisation (CDCO)/Monash University, Epichem and Murdoch University, Australia; Federal University of Ouro Preto, Brazil.
Read more

Project of the Year Awarded to Development of Oxaborole SCYX-7158 for HAT 

In pre-clinical studies, the new drug candidate, SCYX-7158, demonstrated safety and the ability to cross the blood-brain barrier making it efficacious against stage 1 and stage 2 of Sleeping Sickness. In addition, the oral formulation, short treatment duration, and excellent pre-clinical safety profile imply that SCYX-7158 could change the way sleeping sickness is treated and reduce its incidence in humans. Partners include Anacor Pharmaceuticals Inc., SCYNEXIS Inc., Pace University, USA.
Read more

New: 'Open Innovation' Portal

To encourage innovation for neglected diseases, DNDi has joined the WIPO Re:Search initiative and ChemBL to share scientific knowledge gained through its projects and partnerships by placing data on chemical compounds and series in the public domain.   Read more

Event: 60th ASTMH, Philadelphia, USA

DNDi participated in the 60th ASTMH meeting with oral presentations on Leishmaniasis and Chagas Disease, and several poster presentations. Read more